Table 2.
Summary of meta-analyses: hybrid therapy vs sequential and concomitant therapy
| Outcomes | Studies, n | Hybrid group | Control group | RR (95%CI) | I2 | P value for heterogeneity |
| Hybrid vs sequential | ||||||
| Eradication rate (PP) | 6 | 88.6% | 87.8% | 1.03 (0.94-1.12) | 82.2% | < 0.05 |
| Eradication rate (ITT) | 6 | 84.3% | 85.1% | 1.00 (0.89-1.12) | 85.2% | < 0.05 |
| Compliance rate | 5 | 96.0% | 98.0% | 0.99 (0.96-1.02) | 50.4% | > 0.05 |
| Side effect rate | 6 | 30.3% | 28.2% | 1.05 (0.86-1.02) | 37.8% | > 0.05 |
| Hybrid vs concomitant | ||||||
| Eradication rate (PP) | 5 | 91.3% | 92.4% | 1.01 (0.96-1.05) | 56.1% | < 0.05 |
| Eradication rate (ITT) | 5 | 84.8% | 86.7% | 0.99 (0.95-1.03) | 0 | > 0.05 |
| Compliance rate | 4 | 95.8% | 93.2% | 1.03 (1.00-1.05) 1 | 0 | > 0.05 |
| Side effect rate | 4 | 39.5% | 44.2% | 0.93 (0.82-1.05) | 0 | > 0.05 |
1
Statistically significant results. ITT: Intention-to-treat; PP: Per-protocol.